Fabre et al. recently reported that the HumaSens plus point-of-care uric acid (UA) meter performed well in comparison to venous UA in a cohort of 238 diabetic patient [1] . We have performed a service evaluation of the HumaSens2.0 plus UA meter in patients seen in a specialist gout clinic for investigation or review. All patients attending the clinic from August 2017 onward were offered fingerprick testing with results compared to a venous sample analysed using an Abbott colorimetric uricase assay as part of standard care. Summary characteristics of the patients included in the study are given in Table 1 with complete data available in Additional file 1.
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Similar to the results of Fabre et al., we observed a close correlation between the capillary and venous UA levels (Fig. 1) . We observed discrepancies which would influence treatment escalation decisions in just five individuals who had levels of UA close to the 0.3 mmol/l threshold and seven individuals around the 0.36 mmol/l threshold. The performance of capillary uric acid measurements in identifying hyperuricaemic individuals was analysed using ROC curve analysis with an AUC of 99% for detection of venous UA levels above 0.3 mmol/l (Fig. 2a) and an AUC of 98.5% for detection of venous UA levels above 0.36 mmol/l (Fig. 2b) . These results compare favourably with those reported by Fabre et al. and possibly reflect improved performance of the HumaSens2.0 plus device over the earlier HumaSens plus device. We also evaluated the role of haematocrit as this was the only potential confounder identified by Fabre et al. Although haematocrit was associated with capillary UA levels independently of venous UA levels in our population, the addition of haematocrit to a prediction model of venous UA levels yielded a trivial increase in performance (ROC curve analysis AUC 99.2% for UA levels greater than 0.3 mmol/l, and unchanged AUC 98.5% at the threshold of 0.36 mmol/l). On four occasions, 'Lo' error reading was obtained prompting immediate retesting. Three continued to give a 'Lo' reading with all these confirmed on venous testing as being below the reference range of the meter (0.18 mmol/l). The remaining 'Lo' error reading corrected on repeat testing.
Our results confirm the findings of Fabre et al. and confirm the reliability of the HumaSens2.0 plus point-of-care device in a population of gout patients. For the vast majority of patients, these results can reliably inform discussions around treatment compliance and the need for additional therapy, as well as allowing direct prescriptions of additional treatment without the need to recall patients. .8% specificity for venous readings above this same level (within this cohort 100% sensitivity was given by a capillary threshold of 0.28 mmol/l and 100% specificity by a capillary threshold of 0.35 mmol/l). Similarly, fingerprick readings at the 0.36 mmol/l threshold yielded 92.4% sensitivity and 91.9% specificity (with 100% sensitivity seen at a threshold of 0.33 mmol/l and 100% specificity at 0.4 mmol/l)
